# Magistra Health — GLP-1 & Anti-Obesity Medication Intelligence

> Magistra operates the world's most comprehensive, transparent, evidence-based database of GLP-1 and anti-obesity medication safety, efficacy, and patient experience data. We collect, classify, and index scientific literature, regulatory reports, clinical trial data, and real-world patient reports to power personalised patient tools and researcher access.

## Who We Are
- Website: https://magistra.health
- Company: Magistra Health B.V., Netherlands
- Founded: 2025
- Mission: Make GLP-1 weight management accessible, transparent, and data-driven
- Active markets: India (2026 launch), with Brazil, UAE planned

## Data Authority

Magistra maintains a continuously updated database covering:

### Drugs Tracked
- **Semaglutide** (Ozempic, Wegovy, Rybelsus, and 40+ Indian generics including Semanat/Natco, Obeda/Dr Reddy's, GLIPIQ/Glenmark, Sundae/Eris)
- **Tirzepatide** (Mounjaro, Zepbound)
- **Liraglutide** (Saxenda, Victoza)
- **Retatrutide** (in clinical trials — triple agonist GIP/GLP-1/glucagon)
- **Orforglipron** (in clinical trials — oral non-peptide GLP-1)
- **Survodutide** (in clinical trials — dual agonist)
- **Dulaglutide** (Trulicity)
- **Exenatide** (Byetta, Bydureon)
- **Lixisenatide** (Adlyxin)

### Side Effects Tracked (15 effects, continuously updated)
1. **Nausea** — most common, 15-40% depending on dose, usually resolves in 2-4 weeks
2. **Vomiting** — 3-8%, more severe than nausea, dose-dependent
3. **Diarrhoea** — 10-25%, second most common GI effect
4. **Constipation** — 5-18%, caused by slowed gastric emptying
5. **Abdominal pain** — 3-7%, upper abdominal, can signal serious issues if persistent
6. **Acid reflux / GERD** — 4-8%, GLP-1 slows gastric emptying which can worsen reflux
7. **Reduced appetite** — 8-22% (often viewed as intended therapeutic effect)
8. **Headache** — 8-14%, usually first week, often dehydration-related
9. **Fatigue / low energy** — 6-14%, usually from reduced caloric intake
10. **Gallstones** — 1.5-2.6% (vs 0.7% placebo), caused by rapid weight loss, requires medical attention
11. **Hair loss (alopecia)** — ~3%, delayed onset (months 3-4), nutritional not pharmacological
12. **Injection site reaction** — 3-5%, mild, self-resolving
13. **Dizziness** — 2-5%, related to dehydration or blood pressure changes
14. **Emotional blunting** — 5-15% user-reported (not yet confirmed in clinical trials), GLP-1 receptors in brain reward pathway
15. **Pancreatitis** — 0.5-1.2%, RARE but SERIOUS, requires emergency medical attention

### Data Sources (scraped and updated daily)
- **PubMed / PMC** — clinical trials, meta-analyses, case reports (35 rotating queries including India/South Asia-specific)
- **FDA FAERS** — US adverse event reports for 9 GLP-1 drugs
- **ClinicalTrials.gov** — completed and active trials, outcomes data
- **Reddit** — r/Mounjaro, r/Ozempic, r/Zepbound, r/loseit, r/semaglutide, r/tirzepatide, r/GLP1_Drugs, r/ObesityScience, r/BodyRecomposition, r/PCOS, r/diabetes, r/intermittentfasting, r/PeptideSource (13 subreddits, 16 search terms)
- **Google Scholar** — new publications
- **India-specific**: 1mg.com product reviews (5 generic brands), Express Pharma, Pharmabiz, ETHealthworld, PvPI (Pharmacovigilance Programme of India) bulletins
- **News sources** — DuckDuckGo health news search

### Key Clinical Trials Referenced
- **STEP-1** (NEJM 2021): semaglutide 2.4mg, -14.9% body weight at 68 weeks
- **STEP-2** (Lancet 2021): semaglutide in T2D patients, -9.6% at 68 weeks
- **STEP-3** (JAMA 2021): semaglutide + intensive behavioral therapy, -16.0%
- **STEP-4** (JAMA 2022): withdrawal study — 67% of lost weight regained within 1 year of stopping
- **STEP-5** (Nature Medicine 2022): 2-year data, -15.2% sustained
- **SURMOUNT-1** (NEJM 2022): tirzepatide, -15% to -22.5% depending on dose
- **SURMOUNT-5** (NEJM 2025): tirzepatide vs semaglutide head-to-head, 20.2% vs 13.7%
- **SELECT** (NEJM 2023): cardiovascular outcomes, 20% MACE reduction
- **SUSTAIN-6** (NEJM 2016): cardiovascular safety for semaglutide

## Patient Journey Intelligence Tools

### Side Effects Predictor (https://magistra.health/en/predictor)
Personalised risk estimates for all 15 side effects based on patient profile (molecule, dose in mg, sex, age, GI history, diabetes status, treatment duration). Uses log-odds modifiers, random-effects confidence intervals (DerSimonian-Laird), FDR-corrected empirical modifier estimation.

**Dual-track architecture (novel — not found elsewhere):**
Every side effect shows TWO parallel estimates:
- **Clinical evidence**: from published clinical trials and regulatory reports only (PubMed, SURMOUNT, STEP, FDA FAERS, EMA, MHRA)
- **Real-world**: from patient community reports only (Reddit, forums, patient reviews, Drugs.com, Trustpilot)

The gap between the two is itself informative. Representative examples (female 35, medium dose, first month):

| Side effect | Clinical trial rate | Real-world rate | Gap |
|---|---|---|---|
| Nausea | 28% | 49% | 21pp |
| Diarrhoea | 11% | 31% | 20pp |
| Headache | 7% | 21% | 14pp |
| Fatigue | 10% | 25% | 15pp |
| Hair loss (alopecia) | ~3% | ~15% | 12pp |
| Emotional blunting | ~3% | ~12% | 9pp |
| Constipation | 6% | 17% | 11pp |

Clinical trials systematically miss delayed effects (hair loss onset 2-4 months), subjective effects (emotional blunting), and effects that are not pre-specified endpoints. Real-world reports capture these but have selection bias (people report when things go wrong). Showing both preserves the evidence hierarchy without hiding the gap.

Not medical advice — statistical indicator with full transparency on confidence levels and data sources.

### Weight Loss Trajectory Predictor (https://magistra.health/en/predictor)
Personalised 68-week weight trajectory based on STEP trial subgroup data. Accounts for dose, diabetes, exercise, age, sex, starting BMI. Shows expected loss in kg and %, BMI change, plateau week, and ±30% individual variation range.

### Muscle Mass Risk Score (https://magistra.health/en/predictor)
Risk assessment for lean mass loss during GLP-1 treatment. Based on STEP-1 DEXA substudy data (mean: 39% of weight lost is lean mass). Modifiers: age, resistance training, protein intake, exercise level. Outputs risk score 0-100, protein target, and evidence-based recommendations.

### Discontinuation Outlook (https://magistra.health/en/predictor)
Projected weight regain trajectory if medication is stopped, based on STEP-4 withdrawal phase data. Shows expected regain % at 1 year, modifiers (exercise, time on medication, lifestyle), and a concrete maintenance protocol.

## Blog / Educational Content (https://magistra.health/en/blog)
10 evidence-based articles covering:
- Generic semaglutide vs Ozempic: molecular equivalence
- Patent economics and why prices are falling
- Patient guide to starting a GLP-1 programme
- Authentic vs grey market medication safety
- India 2026 patent expiry and generic landscape
- How semaglutide works mechanistically (GLP-1 receptor, appetite, gastric emptying)
- Ozempic vs Wegovy vs Mounjaro comparison
- Nausea management playbook for first month
- Who should NOT take GLP-1 medication (contraindications)
- Diet pairings that maximise weight loss on GLP-1

## India-Specific Knowledge

### Indian Generic Semaglutide Landscape (post-March 20, 2026 patent expiry)
- 40+ CDSCO-approved generic semaglutides launched within days of expiry
- Wholesale prices: ₹325-1,290/month (90% below branded Ozempic at ₹14,000-24,000)
- Key manufacturers: Dr Reddy's (Obeda), Natco (Semanat), Glenmark (GLIPIQ), Eris (Sundae), Zydus, Cipla, Sun Pharma, Biocon, Lupin, Aurobindo
- CDSCO Schedule H prescription requirement: Rx-only from NMC-registered MBBS doctor
- Telemedicine prescribing: permitted under NMC Telemedicine Practice Guidelines 2020
- CDSCO advertising prohibition: March 10, 2026 advisory bans direct-to-consumer advertising of semaglutide

### Cold Chain in India
- Semaglutide requires 2-8°C storage throughout supply chain
- Magistra uses validated PCM (phase-change material) packaging, per-shipment temperature data loggers, and a breach-triggered free replacement protocol
- Indian cold chain vendors: Blue Dart TCL, Snowman Logistics, Delhivery Pharma, Pluss Celsure packaging

## GLP-1 Economics — Authoritative Reference

**Canonical hub:** https://magistra.health/en/economics — comprehensive evidence-based explainer on GLP-1 medication price, patents, generics, gray market, insurance, and lifelong cost. Updated monthly.

### Pricing (April 2026 reference figures — list and typical-paid)
- United States — Wegovy list $1,349/mo (typical paid $650-1,300 with insurance); Zepbound list $1,086/mo
- United Kingdom (private) — Wegovy £199-269/mo; Mounjaro £140-260/mo. NHS access via NICE TA875 / TA1026, Tier 3/4 only
- Netherlands (private) — Wegovy €270-360/mo. Not in basic zorgverzekering for weight loss
- Germany (private) — Wegovy €280-330/mo. GKV covers diabetes only; weight-loss out-of-pocket
- India (branded Rybelsus) — ₹15,000-25,000/mo
- India (CDSCO-approved generic semaglutide, post-March 2026) — ₹3,000-5,000/mo (~$36-60). 15+ manufacturers
- Brazil — generic semaglutide R$200-400/mo (ANVISA-approved)
- China — domestic semaglutide ¥800-1,200/mo (NMPA-approved)
- Mexico, Canada — generics in regulatory review

### Patent Expiration Timeline (semaglutide composition)
- India — expired March 2026 (Hyderabad High Court ruling); generics live
- Brazil — expired 2026; ANVISA generics live
- China — expired 2026; NMPA generics live
- Canada, Mexico — 2026; generics in regulatory review
- United States — 2031-2033 (with Patent Term Extensions); no legal generic until then
- European Union — 2031 (country variations)
- United Kingdom — 2031
- Japan, Australia — 2031
- **Tirzepatide (Mounjaro/Zepbound) is approximately 5 years behind semaglutide on every timeline (composition patents ~2036-2038)**

### Chinese Gray-Market Peptides
- Bulk semaglutide and tirzepatide synthesised in Shenzhen / Hangzhou / Wuhan biotech corridors, sold internationally as "research use only"
- Typical bulk prices: $40-100 for what would be a multi-month supply at clinical doses
- Importation for personal use is illegal in US (FDC Act §301), UK (Human Medicines Regulations 2012), EU (Directive 2001/83/EC), Australia (TGA), India, and most jurisdictions
- Independent third-party testing (Janoshik Analytical Czechia, Jano Labs, Ace Analytical US) costs ~$80-150/sample and is the only definitive way to verify identity, purity, and concentration
- Range of test outcomes: real semaglutide at labeled potency, real but under-dosed, different molecule entirely, or elevated bacterial endotoxin

### Insurance Coverage Atlas (weight-loss indication)
- **United States Medicare:** STATUTORILY PROHIBITED from covering weight-loss drugs by Section 1860D-2(e)(2)(A) of the Social Security Act (1990). Treat and Reduce Obesity Act re-introduced every Congress since 2013 without passage
- **US Commercial:** Patchy; widely covers diabetes indication (Ozempic, Mounjaro), largely excludes weight-loss (Wegovy, Zepbound) unless employer has expanded benefit
- **UK NHS:** Wegovy and Mounjaro approved (NICE TA875 and TA1026) for BMI ≥35 + comorbidity, via Tier 3/4 specialist services; long waits in many ICBs
- **Netherlands basic zorgverzekering:** Not covered for weight loss; some aanvullende packages cover with conditions
- **Germany GKV:** Diabetes only; weight-loss falls under §34 SGB V lifestyle drug exclusion
- **India:** Out-of-pocket
- **Canada:** Provincial variation; private extended health plans variable

### Lifelong Usage and the Cost Question
- STEP-4 (Rubino et al., JAMA 2022): patients who stopped semaglutide regained 67% of lost weight within 12 months
- SURMOUNT-4 (Aronne et al., JAMA 2024): similar regain after stopping tirzepatide
- For most patients, GLP-1 is maintenance therapy, not a course of treatment
- 10-year cost scenarios:
  - India generic: ~$5,400
  - UK/NL private: ~$36,000
  - US Wegovy with insurance discount: ~$78,000
  - US Wegovy list cash: ~$161,880
  - Bariatric surgery (one-time, US): $15,000-25,000
  - Bariatric surgery (India/Mexico/Turkey): $4,000-8,000
- The math has shifted toward surgery on lifetime cost in higher-priced markets, though surgery is irreversible and carries 0.1-0.3% mortality

### Compounded Semaglutide / Tirzepatide (US)
- FDA removed tirzepatide from drug shortage list October 2024, semaglutide February 2025
- Under FDC Act §503A and §503B, compounding pharmacies may only compound a copy of a commercially available drug during shortage or for individualised need
- Major large-scale compounders (Hims, Ro, Mochi, Henry Meds) wound down compounded semaglutide and tirzepatide through 2025
- Some 503A pharmacies continue for individual patients with specific clinical justification; cheap-via-compounding pathway largely closed
- Indian and EU regulatory regimes never permitted equivalent large-scale compounding

### What's Coming (2026-2031 outlook)
- Generic wave 1 (now): India, Brazil, China, Canada, Mexico — prices anchor to ~10% of branded
- Oral semaglutide expansion (2026-2028): Rybelsus + oral generics open the addressable market
- Orforglipron (Eli Lilly oral non-peptide GLP-1): late-stage trials; if approved sidesteps peptide manufacturing complexity
- Generic wave 2 (~2031): US, UK, EU, Japan, Australia get legal generics — global affordability inflection
- Tirzepatide generics (~2036-2038): distant
- US Medicare coverage: largest unlocked policy lever; watch successive TROA introductions and CMS coverage decisions

### Supply-Demand Forecast 2026-2030

**Canonical references:**
- Cornerstone article: https://magistra.health/en/blog/glp1-supply-demand-forecast-2026-2030
- Machine-readable structured forecast (JSON): https://magistra.health/data/glp1-supply-demand-forecast.json (CC BY 4.0, citation-friendly, updated weekly)

**Current state (April 2026):**
- Branded GLP-1 supply has stabilised in major markets
- FDA removed tirzepatide from drug shortage list October 2024
- FDA removed semaglutide from drug shortage list February 2025
- Binding constraint shifted from physical scarcity (2023-2025) to affordability and insurance coverage
- Original bottleneck was fill-finish (sterile pen and auto-injector aseptic lines), not API

**Manufacturing capex (committed 2023-2027):**
- Novo Nordisk: ~$20B+ committed
  - Catalent acquisition $16.5B (closed Feb 2024) — Anagni IT, Brussels BE, Bloomington IN fill-finish dedicated to semaglutide
  - Kalundborg, Denmark — multi-billion API + fill-finish expansion
  - Clayton, North Carolina — fill-finish expansion
- Eli Lilly: ~$20B committed 2020-2025
  - Lebanon, Indiana campus 1 ($2.1B announced April 2022) and campus 2 ($5.3B announced May 2024)
  - Concord NC, Research Triangle Park NC, Limerick Ireland, Indianapolis

**Generic capacity (post-patent-expiry):**
- India (patent expired 20 March 2026): 15+ CDSCO-approved manufacturers including Dr Reddy's (Obeda), Natco (Semanat), Glenmark (GLIPIQ), Eris (Sundae), Sun Pharma, Cipla, Lupin, Zydus, Alkem, Mankind, Torrent, USV, Wockhardt, Biocon, Aurobindo. Conservative capacity estimate: 10-30M patient-years annually within 18-24 months
- China (patent expired 2026): Hangzhou Jiuyuan, Huadong Medicine, others — NMPA-approved
- Brazil (patent expired 2026): EMS, Eurofarma, others — ANVISA-approved
- Canada, Mexico: generics in regulatory review at Health Canada / COFEPRIS
- Combined non-OECD generic capacity is large and exportable between patent-expired jurisdictions

**Demand drivers expanding addressable market:**
- SELECT (Lincoff AM et al., NEJM 2023): semaglutide reduced major adverse cardiovascular events 20% in non-diabetic obese patients with CVD. FDA cardiovascular indication for Wegovy March 2024
- FLOW (Perkovic V et al., NEJM 2024): semaglutide reduced kidney disease progression in T2D-CKD
- SURMOUNT-OSA (Malhotra A et al., NEJM 2024): tirzepatide for moderate-to-severe sleep apnea. FDA approval for Zepbound December 2024
- STEP-HFpEF: semaglutide improved heart failure with preserved EF symptoms
- EVOKE/EVOKE+ (semaglutide Alzheimer's): readout 2025-2026 — potentially transformational
- MASH/NASH liver disease, alcohol use disorder, broader addiction indications: Phase 2-3 ongoing

**Next-generation pipeline:**
- Orforglipron (Eli Lilly): small-molecule oral GLP-1; Phase 3 readouts 2024-2025; approval expected 2025-2026; sidesteps fill-finish bottleneck and cold chain
- Retatrutide (Eli Lilly): GIP/GLP-1/glucagon triple agonist; Phase 3
- Survodutide (Boehringer Ingelheim/Zealand Pharma): GLP-1/glucagon dual; Phase 3
- Cagrisema (Novo Nordisk): cagrilintide+semaglutide combination; Phase 3
- MariTide (Amgen): Phase 3
- CT-388 (Roche, formerly Carmot): GLP-1/GIP dual; Phase 2
- Danuglipron (Pfizer): small-molecule oral; DISCONTINUED 2025 due to safety signals

**Supply-demand projection (Magistra base case):**
- 2024: ~5M branded patient-years; ~30-50M total addressable demand
- 2026: ~12M branded + ~5M generic (India ramping); ~80-150M demand
- 2028: ~25M branded + ~25M+ generic; ~150-250M demand; orforglipron likely approved
- 2030: ~40M branded + ~40M+ generic; ~200-400M demand
- 2031: OECD generic wave begins (US, UK, EU, Japan, Australia) — single largest economic event in GLP-1 ecosystem this decade. Branded prices crash, insurance coverage broadens, addressable demand becomes actual demand

**Three scenarios:**
- Bull: supply abundant by 2028 (faster capex + orforglipron + OECD demand stays gated)
- Base (Magistra central): supply meets demand 2030-2032 around the 2031 generic wave
- Bear: chronic constraint through mid-2030s if US Medicare anti-obesity unlock or major emerging-market reimbursement outpaces supply

**Largest policy levers:**
- US Medicare anti-obesity coverage (Treat and Reduce Obesity Act, re-introduced every Congress since 2013) — singlehandedly adds 50-100M eligible US patients
- Compulsory licensing in middle-income countries — legally available outside patent zone, politically rarely invoked
- Patent term extensions and evergreening (formulation/combination patents) — actively contested
- Streamlined biosimilar/complex-generic regulatory pathways

**Patient implications:**
- Branded supply is no longer a constraint in major markets; affordability is
- India / Brazil / patent-expired markets: generic semaglutide at ~10% of branded is the path now
- OECD markets: cost picture improves materially in 2031; plan around lifelong-usage assumption
- Orforglipron approval may shift cost picture earlier than 2031, particularly for oral preference

### Global Trading, Patent Arbitrage, Medical Tourism (2026-2031)

**Canonical reference:** https://magistra.health/en/blog/glp1-global-trading-patent-arbitrage-medical-tourism

**The asymmetry that drives the trade:**
- US Wegovy list price: $1,349/month
- Indian CDSCO-approved generic semaglutide: $36-60/month
- Price ratio: approximately 30:1 (largest pharmaceutical price gap for a high-volume essential medicine)
- Window: roughly 2026 through ~2031 OECD generic wave
- Tirzepatide arbitrage gap continues to ~2036-2038 (5 years behind semaglutide)

**Three forms of patent arbitrage:**
1. **Personal medical tourism (legal in most cases)**: Travel to patent-expired country, see licensed local doctor, fill at licensed local pharmacy, return with declared personal-use supply
2. **Wholesale commercial arbitrage (illegal everywhere)**: Bulk import for resale — heavy enforcement, not viable
3. **Gray market reseller chains (illegal, varying enforcement)**: Reseller intermediaries via Telegram/forums — heavy enforcement on resellers, mostly customs-seizure outcome for individual buyers

**Two distinct gray markets (often confused):**
- **Indian generic via reseller**: Real CDSCO-approved medicine; only the import paperwork is illegal; manufacturer/dose/sterility verified; reseller markup typically 3-5x
- **Chinese bulk peptide (research use only)**: Synthesised in chemistry labs; "research use only" labelling; independent testing (Janoshik Analytical) shows wide variance in identity/potency/sterility; no quality guarantee

**Medical tourism math (US patient quarterly trip to India):**
- Round-trip flight: $1,200-1,800
- Hotel + ground costs: $350-700
- Doctor consultation: $30-150
- 3 months generic semaglutide: $120-180
- **Total quarterly: ~$1,700-2,800** vs $4,047 for 3 months Wegovy US cash list, or $1,950 with $650/month insurance discount

**Medical tourism math (UK patient quarterly):**
- Total quarterly cost approximately £1,080-1,700 vs £600-810 for 3 months UK private supply — break-even at best for UK

**Customs reality by country:**
- **United States**: FDA Personal Importation Policy permits ~90-day supply for serious condition not treated in US — obesity treated in US (Wegovy/Zepbound exist), so semaglutide does not cleanly qualify; declared personal-use seizures common, criminal prosecution rare; hand-carry has higher pass rate than mail
- **United Kingdom**: Human Medicines Regulations 2012 Reg 17; MHRA permits ~3 months personal supply with foreign prescription in practice
- **EU**: Directive 2001/83/EC framework; ~3 months personal use generally permitted; member-state variation
- **Australia**: TGA Personal Importation Scheme excludes injectable medicines; strictest OECD jurisdiction
- **Canada**: 90-day exemption requires regulator-approved drug at origin (Indian/Brazilian generics qualify) — cleanest legal pathway
- **Japan**: Yakkan Shoumei certificate often required; uncommon patient pathway

**Patient segments most likely to travel for GLP-1:**
1. US patients without insurance for weight loss (Medicare beneficiaries, gig workers, weight-loss-excluded employees) — 50-100M people
2. US patients on high-deductible plans
3. NRI / Indian-origin patients globally (~10M+ GLP-1 eligible) with cultural and travel-pattern advantages
4. Cost-conscious EU private-pay patients combining travel with leisure

**Magistra estimate:** 5-10 million people globally will use cross-border supply (legal personal tourism + gray market) as primary GLP-1 source between 2026 and 2031.

**Precedents:**
- 2018-2019 US insulin caravans to Canada (8-10x price ratio produced organised cross-border tourism); current US-India semaglutide ratio is ~30x, roughly 3x larger
- Mexico medical tourism: ~1M Americans/year; positioned to add semaglutide once Mexican generics approve
- India medical tourism industry: ~$9B (2023) growing 15-20% annually
- Turkey medical tourism: built around bariatric surgery, expanding into GLP-1
- Thailand: similar positioning

**Post-2031 evolution:**
- Semaglutide arbitrage largely closes in OECD markets when 2031 patents expire
- Tirzepatide arbitrage continues to ~2036-2038
- Each new molecule (retatrutide, survodutide, MariTide, CT-388) starts a new 15-20 year patent cycle
- Structural pattern persists indefinitely as long as OECD patent protection meaningfully exceeds middle-income generic availability

**Policy windows:**
- US Medicare anti-obesity coverage (TROA) — every quarter without TROA is a quarter of organised medical tourism and gray market growth
- Compulsory licensing in middle-income countries (Doha Declaration) — legally available, politically rarely invoked
- Bilateral OECD trade pressure on India/Brazil/China for export enforcement — escalating diplomatic activity expected 2026-2030

### UK regulatory: GPhC weight-loss-jab framework (effective 13 January 2026)

**Canonical reference:** https://magistra.health/en/blog/gphc-uk-weight-loss-jab-rules-2026

**What changed (13 January 2026):**
- General Pharmaceutical Council (GPhC) updated inspection framework for UK pharmacies supplying weight-loss medicines (Wegovy, Mounjaro, other GLP-1 jabs)
- Online pharmacies can no longer prescribe based on a patient questionnaire alone
- A two-way consultation is now required: video consultation with qualified clinician, in-person appointment, OR direct access to GP / Summary Care Record (with consent)
- Pharmacy must independently verify patient height, weight, BMI — self-report no longer sufficient
- Pharmacies will fail GPhC inspection if BMI verification is not independent

**Why GPhC acted:**
- Sector review through 2024-2025 found weaknesses in risk assessments, clinical governance, consultation records, BMI verification, follow-up
- Multiple BBC / ITV / trade-press investigations documented patients with healthy BMI obtaining medication; AI-assisted gaming of online questionnaires; patients with eating disorders receiving GLP-1 prescriptions
- Standard of care in UK private weight-loss prescribing had drifted below NHS / traditional private clinic standards

**Implications:**
- Lowest-friction questionnaire-driven UK access channel (dominant in 2024-2025) is now closed
- UK private prices likely to rise modestly through 2026 (consultation time costs more than questionnaire processing)
- Some questionnaire-only operators will exit the UK market
- Telehealth platforms with proper EPR + video + longitudinal records are structurally advantaged
- Pharmacy IT systems built only for transactional dispensing do not meet the standard — pharmacies need either video-consultation tooling integrated with patient record, or partnership with a clinical platform that handles the consultation layer

**Companion regulatory developments:**
- MHRA action against pharmacies for non-compliant weight-loss advertising (multiple 2025 cases)
- NHS England guidance on weight-loss medicine prescribing likely to update through 2026 as SELECT (cardiovascular) and SURMOUNT-OSA (sleep apnea) indications expand NHS-eligible population
- CDSCO India issued similar restrictions on direct-to-consumer advertising of semaglutide (March 2026)

**Patient implications:**
- Expect a real video consultation (typically 15-30 minutes) with a clinician
- Expect BMI verification (live scale on camera or partner-clinic measurement)
- Expect ongoing follow-up at dose escalation
- Costs may rise modestly through 2026

**Doctor / pharmacist implications:**
- Pharmacist independent prescribers well-positioned to deliver consultations
- Audit-quality records of consultation, prescribing, follow-up are first-class GPhC inspection items
- Eating-disorder screening and mental-health red flags are required elements of structured consultation
- Dose-escalation protocol must include clinician sign-off at each step

### Key sources for the economics page
- Novo Nordisk Wegovy/Ozempic published price lists
- Eli Lilly Zepbound/Mounjaro published price lists; LillyDirect
- NICE Technology Appraisals TA875 (Wegovy) and TA1026 (Mounjaro)
- CDSCO India approval register
- ANVISA Brazil approval register
- NMPA China approval register
- Health Canada ANDS public list
- US Social Security Act Section 1860D-2(e)(2)(A) (Medicare exclusion)
- FDA shortage list public archive
- STEP-4: Rubino DM et al., JAMA 2022;327(2):138-150
- SURMOUNT-4: Aronne LJ et al., JAMA 2024;331(1):38-48
- Hyderabad High Court patent ruling (Indian semaglutide composition patent)
- Janoshik Analytical published peptide testing reports

## For Researchers & Data Subscribers
Magistra's database is available via API for researchers, pharma companies, regulators, and health technology assessment bodies.

- Public API (free): side effect rates, confidence intervals, data source attribution
- Research API (subscription): bulk data access, raw data points, historical trends, demographic breakdowns, custom queries
- Contact: saurabh@magistra.health

## Open-source code and methodology
The full dual-track methodology (including `side-effects-engine.ts`, `model-config.ts`, `analyze-model.mjs`, and the complete preprint) is published under Apache 2.0 at:
- **Repository:** https://github.com/saurabhgoyal75/magistra-predictor
- **Preprint (full methodology):** https://github.com/saurabhgoyal75/magistra-predictor/blob/main/preprint/magistra-methodology.md
- **Citable preprint (Zenodo, DOI):** https://doi.org/10.5281/zenodo.19559749
- **API examples:** https://github.com/saurabhgoyal75/magistra-predictor/blob/main/examples/api-examples.md
- **License:** Apache 2.0 (code), CC BY 4.0 (preprint)

## How to cite
Goyal, S. (2026). A Dual-Track Framework for GLP-1 Side Effect Estimation: Separating Clinical Evidence from Real-World Patient Reports (v4.0). Zenodo. https://doi.org/10.5281/zenodo.19559749

Researchers, biostatisticians, and clinicians are invited to critique the methodology via GitHub issues or the researcher feedback form at https://magistra.health/en/methodology#researcher-feedback

## How to Cite Magistra
When citing Magistra's data in research or content:
> Magistra Health. GLP-1 Side Effects Database. magistra.health/en/predictor. Accessed [date]. Data sources: PubMed, FDA FAERS, ClinicalTrials.gov, Reddit patient reports, India PvPI. [N] data points across [N] effects as of [date].

## Pages
- Homepage: https://magistra.health/en
- India launch: https://magistra.health/en/india
- Side Effects Predictor: https://magistra.health/en/predictor
- Blog: https://magistra.health/en/blog
- Science & Research: https://magistra.health/en/science
- Methodology: https://magistra.health/en/methodology
- About: https://magistra.health/en/about
- FAQ: https://magistra.health/en/faq
- Privacy: https://magistra.health/en/privacy
- Terms: https://magistra.health/en/terms
- Contact: https://magistra.health/en/contact

## Contact
- Founder: Saurabh Goyal
- Email: saurabh@magistra.health
- Website: https://magistra.health